ATXS vs. CRDF

Last updated Apr 2, 2026

Compare and contrast key facts about Astria Therapeutics, Inc. (ATXS) and Cardiff Oncology, Inc. (CRDF).

Performance

ATXS vs. CRDF - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Astria Therapeutics, Inc. (ATXS) and Cardiff Oncology, Inc. (CRDF). The values are adjusted to include any dividend payments, if applicable.

ATXS vs. CRDF - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ATXS Astria Therapeutics, Inc.	-3.90%	46.42%	16.41%	-48.42%	176.25%	-58.02%	-63.79%	35.24%	-70.67%	-58.73%
CRDF Cardiff Oncology, Inc.	-42.70%	-35.25%	193.24%	5.71%	-76.71%	-66.59%	1,350.81%	-60.67%	-85.76%	-85.36%

Fundamentals

Market Cap ATXS : $729.71M CRDF : $107.61M
EPS ATXS : -$2.14 CRDF : -$0.69
PS Ratio ATXS : 1.03K CRDF : 234.13
PB Ratio ATXS : 5.29 CRDF : 2.37
Total Revenue (TTM) ATXS : $706.00K CRDF : $459.00K
Gross Profit (TTM) ATXS : $706.00K CRDF : -$11.12M
EBITDA (TTM) ATXS : -$134.05M CRDF : -$47.20M

Returns By Period

ATXS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CRDF

• 1D: -0.62%
• 1M: -17.01%
• YTD: -42.70%
• 6M: -22.60%
• 1Y: -47.39%
• 3Y*: -0.81%
• 5Y*: -30.09%
• 10Y*: -41.56%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ATXS vs. CRDF — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRDF

CRDF Risk / Return Rank: 18
CRDF Sharpe Ratio Rank: 16
CRDF Sortino Ratio Rank: 20
CRDF Omega Ratio Rank: 19
CRDF Calmar Ratio Rank: 15
CRDF Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATXS vs. CRDF - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Astria Therapeutics, Inc. (ATXS) and Cardiff Oncology, Inc. (CRDF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	ATXS	CRDF	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.57	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.30	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.39	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.23	—

Correlation

The correlation between ATXS and CRDF is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ATXS vs. CRDF - Dividend Comparison

Neither ATXS nor CRDF has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	ATXS	CRDF	Difference
Max Drawdown Largest peak-to-trough decline	—	-99.96%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-66.74%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-90.44%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.84%	—
Current Drawdown Current decline from peak	—	-99.92%	—
Average Drawdown Average peak-to-trough decline	—	-86.06%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	42.87%	—

Volatility

Volatility by Period

	ATXS	CRDF	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	16.19%	—
Volatility (6M) Calculated over the trailing 6-month period	—	63.44%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	83.75%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	99.19%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	105.87%	—

Financials